Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda; osteoporosis, including Actemra, Edirol, and Bonviva; renal diseases consist of Mircera and Oxarol; and neurology/other diseases comprise Hemlibra, CellCept, and Enspryng. It has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, renal diseases, neurology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group; and collaboration and joint research with academia. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.
Revenue of Chugai Pharmaceutical Co., Ltd. (4519.T)
Revenue in 2023 (TTM): $7.18 B
According to Chugai Pharmaceutical Co., Ltd.'s latest financial reports the company's current revenue (TTM) is $7.18 B. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Chugai Pharmaceutical Co., Ltd.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $7.18 B | $4.48 B | $3.04 B | $2.87 B | $2.1 B |
| 2022 | $8.14 B | $5.06 B | $3.63 B | $3.43 B | $2.42 B |
| 2021 | $6.46 B | $4.27 B | $2.91 B | $2.71 B | $1.96 B |
| 2020 | $5.08 B | $3.32 B | $2.12 B | $1.93 B | $1.39 B |
| 2019 | $4.43 B | $2.71 B | $1.51 B | $1.34 B | $1.02 B |
| 2018 | $3.74 B | $2.05 B | $891.89 M | $784.44 M | $597.38 M |
| 2017 | $3.45 B | $1.81 B | $732.63 M | $626.73 M | $469.66 M |
| 2016 | $3.18 B | $1.57 B | $587.11 M | $480.86 M | $346.15 M |
| 2015 | $3.22 B | $1.67 B | $664.75 M | $563.72 M | $394.81 M |
| 2014 | $2.98 B | $1.57 B | $588.1 M | $491.95 M | $329.28 M |
| 2013 | $2.74 B | $1.53 B | $590.65 M | $496.98 M | $328.73 M |
| 2012 | $2.53 B | $1.44 B | $579.74 M | $486.5 M | $311.36 M |
| 2011 | $2.41 B | $1.4 B | $471.74 M | $369.01 M | $227.58 M |
| 2010 | $2.45 B | $1.4 B | $540.44 M | $424.27 M | $267.62 M |
| 2009 | $2.77 B | $1.52 B | $703.65 M | $577.54 M | $365.8 M |
| 2008 | $2.11 B | $1.29 B | $538.16 M | $407.6 M | $253.61 M |
| 2007 | $2.23 B | $1.34 B | $526.52 M | $429.05 M | $258.75 M |
| 2006 | $2.11 B | $1.25 B | $497.59 M | $406.64 M | $248.14 M |
| 2005 | $2.11 B | $1.34 B | $668.41 M | $556.63 M | $346.41 M |
| 2004 | $1.9 B | $1.18 B | $466.32 M | $371.32 M | $220.36 M |
| 2003 | $1.5 B | $961.87 M | $387.32 M | $318.06 M | $183.73 M |